Latest Immutep News & Updates

See the latest news and media coverage for Immutep. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Immutep

Biotechnology company developing LAG-3 immunotherapies

immutep.com
Headquarters
Sydney, Australia
Company type
Public company
Number of employees
10–60

Last updated

Latest news about Immutep

In short: Immutep halted its Phase III TACTI-004 trial due to futility while advancing its IMP761 program and facing several securities fraud class actions.

Company announcements

Immutep

Immutep discontinues TACTI-004 Phase III trial

IDMC recommends halt after futility analysis; root cause under review. IMP761 Phase I advances with favorable safety. Cash at A$110.6M extends to H1 CY2028.

Unlock all announcements with a

Media coverage

Morningstar

IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should...

On May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ...

Unlock all articles with a

Never miss news about Immutep

Track Immutep and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Immutep competitors & trending companies

Browse news for competitors to Immutep and other trending companies.